About US
Contact us
-
Alnylam & MIT Collaborators Report New Preclinical Research on Systemic Delivery of RNAi TherapeuticsAlnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MI2010/1/11
-
Daiichi Sankyo' Subsidiary Acquires PharmaForcePharmaForce product line will be marketed by American Regent Luitpold Pharmaceuticals, a US subsidiary of Daiichi Sankyo, and PharmaForce have announced that PharmaForce has been acquired by Luitpold2010/1/8
-
SFDA releases medical sodium hyaluronate products management classification announcementIn order to strengthen the supervision and management to medial sodium hyaluronate (hyaluronic acid sodium) products, further standardize the application and approval procedure and ensure the2010/1/8
-
Dr. Stefan Beckmann is the new head of Care Chemicals and Formulators Europe at BASFLudwigshafen , Germany – January 7, 2010 – Since January 1, 2010 Dr. Stefan Beckmann has been head of the Care Chemicals and Formulators Europe unit at BASF. He succeeds Dr. Friedrich Seitz, who will2010/1/8
-
United Drug Selects Pilgrim Software As Global Quality & Compliance Solution ProTampa, FL - Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, recently announced that United Drug plc, a leading international2010/1/7
-
BASF products help to construct the tallest building in the worldLudwigshafen , Germany/Dubai, United Arab Emirates – January 4, 2010 – Rising more than 800 meters to 160 stories, the Burj Dubai appears to touch the Dubai skies. On January 4, 2010, the tallest buil2010/1/7
-
A winter jacket for your radiator· Insulation wallpaper made from BASF's Neopor with improved insulation performance The insulation material manufacturer Saarpor, Germany is now using Neopor®, BASF’s expandable polystyrene (EPS2010/1/7
-
FDA Orphan Drug Workshopssource: web of SFDA20100106(3).rar2010/1/6
-
Pearl Therapeutics Reports Positive Results From PT005 TrialFor the treatment of chronic obstructive pulmonary disease Pearl Therapeutics (Pearl) has reported positive results from phase 2a dose-ranging study of PT005, a formoterol fumarate hydrofluoroalkane2010/1/6
-
Intercell Initiates Efficacy Trial For TD Vaccine System In AsiaTo evaluate efficacy and enterotoxigenic E coli incidence of vaccinated European travelers to India Intercell has started a phase II study in India as part of its clinical development program, for th2010/1/6